AI Article Synopsis
- Lurasidon is a new second-generation antipsychotic drug known for its safety and low side effect profile, mainly impacting dopamine and serotonin receptors.
- A case study is presented involving a 39-year-old man with paranoid schizophrenia who developed neutropenia while taking lurasidone, but his condition improved after discontinuing the drug and receiving supplementation.
- The findings highlight the importance of regularly monitoring blood cell levels in patients on second-generation antipsychotics to detect risks like neutropenia and agranulocytosis.
Article Abstract
Purpose: Lurasidon is a relatively new, second-generation antipsychotic drug with an interesting receptor profile. It is considered to be safe and has a low risk of side effects. It is a substance with a multi-receptor mechanism of action: it mainly blocks dopaminergic D2 and serotonergic 5-HT2A receptors. According to the Summary of Product Characteristics, the adverse reaction of neutropenia was too rare to enable the estimation of its frequency.
Case Description: A case of 39-year-old patient is presented in the article, diagnosed with paranoid schizophrenia, who developed neutropenia as a result of treatment with lurasidone. After the discontinuation of lurasidone and recommended supplementation, the blood test results gradually improved and finally reached the normal range.
Comment: This case report shows the need for regular monitoring of blood cell parameters in patients treated with second-generation antipsychotics, as there is a risk of neutrocytopenia or even agranulocitosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683055 | PMC |
| http://dx.doi.org/10.5114/ppn.2023.132474 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!